Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Single-Center Pilot Study

Publisher： Karger

E-ISSN： 2296-5262|29|7|308-313

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.29, Iss.7, 2006-07, pp. : 308-313

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors

By  

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 35-38

Karger

Access to resources Recommend Favorite

A phase II trial of a multi‐agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 4, 2014-04 ,pp. : 636-642

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study

By  

Oncology Research and Treatment, Vol. 30, Iss. 12, 2007-11 ,pp. : 629-635

Karger

Access to resources Recommend Favorite

Combined heart–liver transplantation: a single‐center experience

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 7, 2015-07 ,pp. : 828-834

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 10, 2015-10 ,pp. : 1717-1724

John Wiley & Sons Inc

Access to resources Recommend Favorite